{"filing":{"accession_number":"0001213900-26-077127","cik":"0001728328","ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-07-10","report_date":null,"primary_document":"ea0297284-8k425_inmed.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026077127/ea0297284-8k425_inmed.htm"},"events":[{"id":17306,"run_id":15486,"accession_number":"0001213900-26-077127","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"InMed entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics on July 6, 2026, amending the definitive merger agreement dated May 19, 2026 to clarify transaction sequencing, financing mechanics, and tax treatment. The all-stock merger constitutes a change of control and is expected to close in Q4 2026, subject to shareholder approval and other customary conditions.","company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","filing_date":"2026-07-10","form":"8-K","submitted_at":null,"items":[{"id":15699,"accession_number":"0001213900-26-077127","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"InMed entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics on July 6, 2026, amending the definitive merger agreement dated May 19, 2026. The amendment clarifies transaction sequencing, financing mechanics, and tax treatment of the all-stock merger. This is a material amendment to a material definitive agreement governing a merger transaction that would constitute a change of control and is expected to close in Q4 2026, subject to shareholder approval and other customary conditions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T20:03:46.585140+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15700,"accession_number":"0001213900-26-077127","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"InMed announced entry into an amendment to a previously announced definitive merger agreement with Mentari Therapeutics and filed a Form S-4 registration statement with the SEC. The disclosure explicitly states the companies \"entered into the Amendment\" to the merger agreement and filed the S-4 \"in connection with the proposed merger.\" This is a material acquisition activity involving a change of control through an all-stock merger expected to close in Q4 2026, subject to shareholder approval and regulatory conditions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T20:03:46.585140+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15699,"accession_number":"0001213900-26-077127","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"InMed entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics on July 6, 2026, amending the definitive merger agreement dated May 19, 2026. The amendment clarifies transaction sequencing, financing mechanics, and tax treatment of the all-stock merger. This is a material amendment to a material definitive agreement governing a merger transaction that would constitute a change of control and is expected to close in Q4 2026, subject to shareholder approval and other customary conditions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T20:03:46.585140+00:00","company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","filing_date":"2026-07-10"},{"id":15700,"accession_number":"0001213900-26-077127","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"InMed announced entry into an amendment to a previously announced definitive merger agreement with Mentari Therapeutics and filed a Form S-4 registration statement with the SEC. The disclosure explicitly states the companies \"entered into the Amendment\" to the merger agreement and filed the S-4 \"in connection with the proposed merger.\" This is a material acquisition activity involving a change of control through an all-stock merger expected to close in Q4 2026, subject to shareholder approval and regulatory conditions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T20:03:46.585140+00:00","company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","filing_date":"2026-07-10"}]}